N/A N=150 Lidocaine and Prevention of Chronic Pain
Surgery
Primary: Number of Participants With Chronic Persistent Pain 3 Months After Surgery as Determined by Character Severity (Yes/no). — 2; 6 participants — p=.19
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=153 Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support)
Intracranial Aneurysms
Primary: Primary Effectiveness Composite Success "Number of Participants With Primary Effectiveness Composite Success (100% Aneurysm Occlusion Without Clinically Significant…
N/A N=60 Effect General and Regional Anesthesia on Glycocalyx
Anesthesia · Glycocalyx · Perfused Boundary Region
Primary: Change in Perfused Boundary Region (PBR) — 2.20; 2.09 micrometer
Phase 3 N=2,231 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Acute Migraine
Primary: Percentage of Participants Who Are Headache Pain Free — 28.2; 32.2; 15.3 percentage of participants — p=<0.001
Phase 1 N=24 Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
Migraine
Primary: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) — 261; 294; 220 nanograms per milliliter (ng/mL)
N/A N=15 Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
Prostate Cancer · Adenocarcinoma of the Prostate Stage I · Adenocarcinoma of the Prostate Stage II
Primary: Comparison of Rectal Volume Receiving 70 Gy or More With CT Versus MRI-planned Prostate Radiotherapy. — 4.9; 9.3 cubic centimeters
Phase 1 N=37 BI 443651 Methacholine Challenge
Asthma
Primary: Absolute Change From Baseline in Maximum Forced Expiratory Volume Within 1 Second (FEV1) Reduction Following Bolus Methacholine Challenge in Part 1 — 0.018; 0.390…
Phase 3 N=396 Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Metabolism and Nutrition Disorder · Obesity
Primary: Change in Body Weight (%) — -6.0; -1.5; -6.5; -1.7 Percentage change — p=< .0001
Early Phase 1 N=28 Fatty Acid Radiotracer Comparison Study in Heart Failure Patients
Heart Failure · Obesity · Type 2 Diabetes Mellitus
Primary: The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With…
N/A N=2,158 Achieving Patient-Centered Care and Optimized Health In Care Transitions by Evaluating the Value of Evidence
Care Transitions
Primary: Hospital Readmission — .956; .949; .698; .972 odds ratio
N/A N=487 The SUCCEED Trial of Secondary Stroke Prevention
Stroke · Secondary Stroke Prevention
Primary: Systolic Blood Pressure — 133.1; 136.9 mm Hg — p=0.73
N/A N=15 Functional MRI Use in Prostate Radiation Treatment Planning
Prostate Cancer
Primary: Number of Participants With Adverse Events — 0 Participants
N/A N=84 Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking
Alcohol Drinking · Alcohol Intoxication · Alcoholism
Primary: Drinks Per Drinking Day — 5.12; 5.64; 4.95; 5.48 drinks per drinking day
Phase 2 N=100 A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older
Healthy
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) After First Vaccination — 38.7; 20.0 Percentage of participants
N/A N=48 Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis
Postmenopausal Osteoporosis · Osteopenia · Jaw, Edentulous, Partially
Primary: Marginal Bone Level Alterations — -0.15; -0.06 millimeter